MRK · News · 20261106N

Melanoma Vaccine Collaboration

Merck & Co., Inc. · 2026-11-06 · Importance 34 · Surprise 42

Moderna's personalized cancer vaccine, being developed with Merck, was cited as benefiting from positive Phase 3 melanoma trial results. The report connected those results to Moderna's stock performance but provided no additional trial data, launch timing, or commercial-demand details. It did not identify a Merck segment or geographic market affected.

Key facts

• Merck is developing a personalized cancer vaccine with Moderna, and the vaccine had positive Phase 3 melanoma trial results. source